SARS-CoV-2 (COVID-19) Human IgM/IgG Assay Kit
COVID-19 Human IgM IgG Assay Kit is an indirect enzyme-linked immunoassay (ELISA) for qualitative determination of COVID-19 human serum IgM and IgG.
Principle of the Assay Qualitative determination of target protein concentration is achieved by an indirect ELISA format. In essence, COVID-19 Spike Protein (S) is added to the microtiter wells. The COVID-19 S protein is captured by target-specific primary (1°) antibodies while the HRP-conjugated secondary (2°) antibodies bind the Fc region of the 1° antibody. Through this binding, the HRP enzyme conjugated to the 2° antibody can catalyze a colorimetric reaction upon substrate addition.
Product Name: COVID-19 Human IgM IgG Assay Kit
Sample Type: Serum
Intended Use: COVID-19 Human IgM IgG Assay Kit is an indirect enzyme-linked immunoassay (ELISA) for detection of human IgM and IgG antibodies against COVID-19 virus in human serum.
Detection Method: Colorimetric
Quality Control Testing: Serial dilution
Regulatory/Restrictions: For Research Use Only
– COVID-19 tag fusion protein
– Anti-human IgM antibody (HRP)
– Anti-human IgG antibody (HRP)
– Anti-tag antibody (HRP)
– 96-Well COVID-19 Spike Protein Coated Microplate
– 10x PBST
– TMB Reagent
– Stop Solution
Unopened Kit: Store COVID-19 fusion protein -80°C.
Store Anti-human IgM antibody (HRP), Anti-human IgG antibody (HRP) and Anti-tag antibody (HRP) at -20°C.
Avoid repeated freezing and thawing.
Corona Virus Disease 2019 (COVID-19) is caused by the SARS-associated coronavirus 2 (SARS-CoV-2), which was first identified in a respiratory disease outbreak in Wuhan City, Hubei Province, China. It has since been responsible for a global pandemic. SARS-CoV-2 is a single-stranded RNA virus with positive polarity and belongs to the genus of beta-coronaviruses, which also includes SARS CoV (2003) and MERS CoV (2012). Like all other corona viruses, the genome of SARS CoV-2 (2019-nCoV) encodes the spike protein, the envelope protein, the membrane protein and the nucleocapsid protein.
ELISA kits for COVID-19 diagnostics
|COVID-19 positive patients display a variety of symptoms with a large range of severity. Current research guidance suggests the length of time from initial infection with SARS-CoV-2 and appearance of first symptoms can be up to 14 days. RT-qPCR tests performed in hospital to confirm diagnosis in acute patients. This type of test examines the genetic material of the virus and give a positive result only if the virus is still present at a critical level. The tests are unable to identify individuals who have recovered.|
The GA CoV-2 ELISA kits are serological tests that identify virus-specific antibodies in patients both during and post infection. Understanding the level of population exposure to SARS-CoV-2 and the number of recovered patients is key to a resilient pandemic response. Our simple GA CoV-2 Two Step ELISA confirms active cases and can indicate the level of immune protection following recovery by specifically identifying the IgG response to N-, S1- and S2- proteins are determined using GA CoV-2 IgG+ EIA confirmatory test.